Effects Of Zoledronic Acid On The Expression Of Vascular Endothelial Growth Factor-C And Cyclooxygenase-2 Protein In Patients With Advanced Non-small Cell Lung Cancer

Objective:To investigate the clinical effects of zoledronic acid in patients with advanced non-small cell lung cancer and its effects on the levels of vascular endothelial growth factor-C(VEGF-C)and cyclooxygenase-2(COX-2).METHODS:Sixty-eight patients from our hospital with advanced non-small cell lung cancer with bone metastases who were treated between February 2017 and April 2018 were enrolled.The computer-based random number method was divided into control group(n=34)and observation group(n=34).The control group was treated with TP chemotherapy.The observation group was treated with zoledronic acid on the basis of the control group,and the effect of the patient was evaluated after 3 cycles.The specific sequence of bone alkaline phosphatase(BALP),type I procollagen N-terminal propeptide(PINP)and type I collagen carboxy terminal peptide ? was measured by immunoelectrochemiluminescence(BAT)before and after treatment.?-crosslaps);ELISA test for vascular endothelial growth factor-C and COX-2 levels;statistics and recording of post-treatment rash,muscle and joint pain,myelosuppression,arrhythmia,kidney The incidence of dysfunction and headache fever was compared between the two groups and the effects of VEGF-C and COX-2 levels.Results:The levels of BALP,PINP,?-crosslaps in the observation group were lower than those in the control group(P<0.05).The levels of VEGF-C and COX-2 in the observation group were lower than those in the control group(P<0.05);The total effective rate of analgesia in the observation group was significantly higher than that in the control group after three cycles of treatment(P<0.05);the incidence of rash,muscle and joint pain,myelosuppression,arrhythmia,renal dysfunction and headache fever in the observation group and the control group were not statistically significant(P>0.05)Conclusion;The use of zoledronic acid in patients with advanced non-small cell lung cancer with bone metastasis can improve the biochemical markers of bone turnover,reduce the levels of VEGF-C and COX-2,effectively improve the analgesic effect,and have high drug safety.It is worthy of popularization and application.